BioCentury | Jun 11, 2020
Finance
Checkmate raises $85M series C to support new indications for TLR9 agonist
...Checkmate Pharmaceuticals Inc., joined by fellow new investors Medicxi Ventures, Omega Funds, Clough Capital Partners, Sectoral Asset Management...
...Immunotherapy of Cancer Longitude Capital Novo Holdings A/S Sofinnova Investments Inc. venBio Partners F-Prime Capital Partners Decheng Capital Medicxi Ventures Omega Funds Clough Capital Partners Sectoral Asset Management Inc. American...
...Immunotherapy of Cancer Longitude Capital Novo Holdings A/S Sofinnova Investments Inc. venBio Partners F-Prime Capital Partners Decheng Capital Medicxi Ventures Omega Funds Clough Capital Partners Sectoral Asset Management Inc. American...